Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system

Acta Neuropathologica

Volumn 130, Issue 2, 2015, Pages 297-298

  Kieseier, Bernd C ^a   Wiendl, Heinz ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; TRANSCRIPTION FACTOR NRF2; FUMARIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; AUTOPSY; BRAIN TISSUE; DEMYELINATION; DRUG MECHANISM; GLIA CELL; GRAY MATTER; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LETTER; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; OLIGODENDROGLIA; PRIORITY JOURNAL; WHITE MATTER LESION; ANIMAL; BRAIN; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MALE; METABOLISM; NERVE CELL; SYNAPSE;

ANIMALS; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FUMARATES; HUMANS; MALE; MICROGLIA; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEURONS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OLIGODENDROGLIA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SYNAPSES;

EID: 84937811633     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1457-5     Document Type: Letter

References (11)

1. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Kohl J, Offermanns S, Wettschureck N, Schwaninger M (2014) Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 124:2188–2192
2. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097
3. Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291–2303
4. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098–1107
5. Gold R, Linker RA, Stangel M (2012) Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 142:44–48
6. Licht-Mayer S, Wimmer I, Traffehn S, Metz I, Brück W, Bauer J, Bradl M, Lassmann H (2015) Cell type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol. doi:10.1007/s00401-015-1452-x
7. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678–692
8. Parodi B, Rossi S, Morando S, Cordano C, Bragoni A, Motta C, Usai C, Wipke BT, Scannevin RH, Mancardi GL, Centonze D, Kerlero de Rosbo N, Uccelli A (2015) Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. doi:10.1007/s00401-015-1422-3
9. Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145:101–107
10. Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S (2015) Gaps between aims and achievements in therapeutic modification of neuronal damage (“neuroprotection”). Neurotherapeutics 12:449–454
11. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in vitro model of brain inflammation. J Neuroinflamm 7:30